-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Insider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells 4,168 Shares of Stock
Insider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells 4,168 Shares of Stock
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) insider Stephen F. Betz sold 4,168 shares of the firm's stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $21.01, for a total transaction of $87,569.68. Following the completion of the sale, the insider now owns 100,598 shares in the company, valued at $2,113,563.98. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Crinetics Pharmaceuticals Stock Performance
NASDAQ:CRNX opened at $20.27 on Tuesday. The company has a 50-day moving average of $20.63 and a 200-day moving average of $20.13. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -6.87 and a beta of 1.20. Crinetics Pharmaceuticals, Inc. has a 52 week low of $15.91 and a 52 week high of $28.95.
Get Crinetics Pharmaceuticals alerts:Hedge Funds Weigh In On Crinetics Pharmaceuticals
Hedge funds and other institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC lifted its holdings in Crinetics Pharmaceuticals by 70.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 8,478 shares of the company's stock valued at $158,000 after purchasing an additional 3,503 shares during the last quarter. Dupont Capital Management Corp lifted its holdings in Crinetics Pharmaceuticals by 36.3% during the 2nd quarter. Dupont Capital Management Corp now owns 8,629 shares of the company's stock valued at $161,000 after purchasing an additional 2,297 shares during the last quarter. Group One Trading L.P. lifted its holdings in Crinetics Pharmaceuticals by 31.6% during the 1st quarter. Group One Trading L.P. now owns 7,318 shares of the company's stock valued at $161,000 after purchasing an additional 1,759 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Crinetics Pharmaceuticals by 17.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,493 shares of the company's stock valued at $164,000 after purchasing an additional 1,110 shares during the last quarter. Finally, Arizona State Retirement System bought a new position in Crinetics Pharmaceuticals during the 2nd quarter valued at about $188,000. 94.42% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Separately, SVB Leerink raised their price target on shares of Crinetics Pharmaceuticals from $36.00 to $39.00 and gave the stock an "outperform" rating in a research report on Thursday, May 26th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $39.67.Crinetics Pharmaceuticals Company Profile
(Get Rating)
Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).
Featured Stories
- Get a free copy of the StockNews.com research report on Crinetics Pharmaceuticals (CRNX)
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) insider Stephen F. Betz sold 4,168 shares of the firm's stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $21.01, for a total transaction of $87,569.68. Following the completion of the sale, the insider now owns 100,598 shares in the company, valued at $2,113,563.98. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
CRinetics制药公司(纳斯达克代码:CRNX-GET Rating)内部人士斯蒂芬·F·贝茨在9月15日(星期四)的一笔交易中出售了4,168股该公司股票。该股以21.01美元的平均价格出售,总成交金额为87,569.68美元。出售完成后,这位内部人士现在拥有该公司100,598股,价值2,113,563.98美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,可以通过这个超级链接获得。
Crinetics Pharmaceuticals Stock Performance
Crinetics制药类股表现
NASDAQ:CRNX opened at $20.27 on Tuesday. The company has a 50-day moving average of $20.63 and a 200-day moving average of $20.13. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -6.87 and a beta of 1.20. Crinetics Pharmaceuticals, Inc. has a 52 week low of $15.91 and a 52 week high of $28.95.
纳斯达克:CRNX周二开盘报20.27美元。该公司的50日移动均线切入位在20.63美元,200日移动均线切入位在20.13美元。该公司市值为10.9亿美元,市盈率为-6.87倍,贝塔系数为1.20。Crinetics PharmPharmticals,Inc.的52周低点为15.91美元,52周高位为28.95美元。
Hedge Funds Weigh In On Crinetics Pharmaceuticals
对冲基金买入Crinetics制药公司
Hedge funds and other institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC lifted its holdings in Crinetics Pharmaceuticals by 70.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 8,478 shares of the company's stock valued at $158,000 after purchasing an additional 3,503 shares during the last quarter. Dupont Capital Management Corp lifted its holdings in Crinetics Pharmaceuticals by 36.3% during the 2nd quarter. Dupont Capital Management Corp now owns 8,629 shares of the company's stock valued at $161,000 after purchasing an additional 2,297 shares during the last quarter. Group One Trading L.P. lifted its holdings in Crinetics Pharmaceuticals by 31.6% during the 1st quarter. Group One Trading L.P. now owns 7,318 shares of the company's stock valued at $161,000 after purchasing an additional 1,759 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Crinetics Pharmaceuticals by 17.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,493 shares of the company's stock valued at $164,000 after purchasing an additional 1,110 shares during the last quarter. Finally, Arizona State Retirement System bought a new position in Crinetics Pharmaceuticals during the 2nd quarter valued at about $188,000. 94.42% of the stock is owned by institutional investors.
对冲基金和其他机构投资者最近对他们在该业务中的头寸进行了调整。Cubist System Strategy LLC在第二季度将其在Crinetics PharmPharmticals的持股增加了70.4%。Cubist Systems Strategy LLC在上个季度额外购买了3503股后,现在拥有8,478股该公司股票,价值15.8万美元。杜邦资本管理公司(DuPont Capital Management Corp)在第二季度增持了36.3%的Crinetics PharmPharmticals股份。杜邦资本管理公司(DuPont Capital Management Corp)目前持有8,629股该公司股票,价值161,000美元,此前该公司在上个季度又购买了2,297股。Group one Trading L.P.在第一季度增持了Crinetics PharmPharmticals 31.6%的股份。Group One Trading L.P.现在持有该公司7318股股票,价值16.1万美元,在上个季度又购买了1759股。苏黎世广东银行第一季度增持Crinetics PharmPharmticals股份17.4%。Zurcher Kantonalbank苏黎世广东银行在上个季度额外购买了1110股后,现在拥有7493股该公司股票,价值16.4万美元。最后,亚利桑那州退休系统在第二季度购买了Crinetics制药公司的一个新头寸,价值约为188,000美元。94.42%的股票由机构投资者持有。
Analysts Set New Price Targets
分析师设定新的价格目标
Crinetics Pharmaceuticals Company Profile
Crinetics制药公司简介
(Get Rating)
(获取评级)
Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).
Crinetics制药公司是一家临床阶段制药公司,专注于罕见内分泌疾病和内分泌相关肿瘤治疗药物的发现、开发和商业化。它的主要候选产品是Paltusotine,这是一种口服选择性非肽生长抑素受体2型激动剂,已经完成了治疗肢端肥大症的第三阶段临床试验,以及治疗类癌综合征和无功能神经内分泌肿瘤(NETS)的第二阶段临床试验。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Crinetics Pharmaceuticals (CRNX)
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- 免费获取StockNews.com的Crinetics PharmPharmticals研究报告(CRNX)
- 甲骨文的短期痛苦可能是你的长期收益
- Lucid看起来像是电动汽车的赢家
- 仍然爱着它:投资者继续光顾麦当劳
- 联邦快递刚刚提供了一个买入机会吗?
- 自动区重新进入拉力赛模式,新高在望
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得《Crinetics PharmPharmticals Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Crinetics制药和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧